^
Association details:
| Biomarker: | TMB-H |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Bavencio (avelumab) (PD-L1 inhibitor) + Inlyta (axitinib) (VEGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer
Published date:
05/02/2023
Excerpt:
We enrolled previously treated patients with advanced or metastatic NSCLC, or untreated, cisplatin-ineligible patients with advanced or metastatic UC. Patients received avelumab 800 mg every 2 weeks (Q2W) and axitinib 5 mg orally two times daily....ORRs were higher in patients with lower TMB (˂median) in the NSCLC cohort and higher TMB (≥median) in the UC cohort.
DOI:
10.1016/j.esmoop.2023.101173
Trial ID:
